Abstract
Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aromatase Inhibitors / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Clinical Trials as Topic
-
Estrogen Antagonists / therapeutic use*
-
Female
-
Humans
-
Tamoxifen / therapeutic use*
Substances
-
Aromatase Inhibitors
-
Estrogen Antagonists
-
Tamoxifen